International Sales Win for PUR Biologics
- PUR Biologics has expanded its sales to include notable international healthcare establishments such as ZIMMER BIOMET and Italian company BPB Medica. The company's expertise in spinal biologics and innovation has garnered global attention. The power of their distribution channels provides revenue opportunities for their spinal biologic products.
- None.
PUR Biologics' robust distribution channels prove to expand sales globally.
IRVINE, CA / ACCESSWIRE / October 24, 2023 / Following a successful engagement at the North American Spine Society (NASS) conference, healthcare technology company, HippoFi, Inc. (OTC PINK:ORHB), announces its wholly owned subsidiary, PUR Biologics, has expanded its sales to include several notable international healthcare establishments.
Ryan Fernan, the Head of PUR Biologics, stated, "Our recent ventures with ZIMMER BIOMET and Italian company BPB Medica, have evoked broader international attention. It's affirming to see our expertise in spinal biologics and innovation garner global acknowledgment."
CJ Wiggins, Executive Chairman and CEO of HippoFi, added, "The power of our distribution channels is a core component to the design of our business, providing us deep coverage and a source of revenue opportunities for our spinal biologic products."
With PUR Biologics' clear trajectory of leadership in the biotech sector, there is incredible momentum building.
To learn more about PUR Biologics' full line of biologic products, visit www.PURbiologics.com.
----
About PUR Biologics
PUR Biologics, a wholly owned subsidiary of HippoFi, Inc. (OTC PINK:ORHB), is a leading biologic company committed to supporting surgeons and hospitals in providing the best care for their patients. PUR Biologics' full line of biologic products currently include: advanced allografts and demineralized extracellular matrixes (d-ECM), innovative synthetic solutions, cellular derived tissues, and a future of next generation regenerative stem cell and growth factor driven therapeutics for treating osteoarthritis and cartilage regeneration.
About HippoFi, Inc.
HippoFi, Inc. delivers its cutting-edge healthcare innovations through an extensive sales channel network while implementing first-to-market solutions in the multibillion-dollar Biotech, Fintech, and Artificial Intelligence (AI) markets. HippoFi comprises three segments: Regenerative Therapeutics, Digital Payments, and AI, which utilize the same customer channels to commercialize solutions, drive revenue, and improve patient outcomes.
HippoFi, Inc. is publicly traded under the symbol: ORHB and is headquartered in Irvine, California. For more information, please visit: www.HippoFi.com and www.PURbiologics.com.
Contact
HippoFi, Inc.
949-323-2330
info@hippofi.com
SOURCE: HippoFi, Inc.
View source version on accesswire.com:
https://www.accesswire.com/795854/international-sales-win-for-pur-biologics
FAQ
What is the news about?
Which international healthcare establishments have PUR Biologics partnered with?
What does PUR Biologics specialize in?
How does the power of their distribution channels benefit the company?
